Abstract
Baricitinib is an oral selective Janus kinase (JAK) 1 and 2 inhibitor used for moderate-to-severe atopic dermatitis (AD). Although its efficacy has been demonstrated in clinical trials [ 1 Reich K. Kabashima K. Peris K. Silverberg J.I. Eichenfield L.F. Bieber T. et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020; 156: 1333-1343 Crossref PubMed Scopus (99) Google Scholar , 2 Simpson E.L. Lacour J.P. Spelman L. Galimberti R. Eichenfield L.F. Bissonnette R. et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br. J. Dermatol. 2020; 183: 242-255 Crossref PubMed Scopus (177) Google Scholar ], the immunological effects of baricitinib on AD are not yet fully understood. Interleukin (IL)− 22 is a key molecule in several inflammatory skin diseases, including psoriasis and AD [ [3] Fujita H. The role of IL-22 and Th22 cells in human skin diseases. J. Dermatol. Sci. 2013; 72: 3-8 Abstract Full Text Full Text PDF PubMed Scopus (120) Google Scholar ]. Here, 14 Japanese adult patients with moderate-to-severe AD who were treated with baricitinib at Gunma University Hospital were analyzed, and the relationship between serum IL-22 levels and disease activity of AD was presented.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
